ATE319691T1 - Prostaglandin endoperoxyde h synthase biosynthese inhibitoren - Google Patents
Prostaglandin endoperoxyde h synthase biosynthese inhibitorenInfo
- Publication number
- ATE319691T1 ATE319691T1 AT98944529T AT98944529T ATE319691T1 AT E319691 T1 ATE319691 T1 AT E319691T1 AT 98944529 T AT98944529 T AT 98944529T AT 98944529 T AT98944529 T AT 98944529T AT E319691 T1 ATE319691 T1 AT E319691T1
- Authority
- AT
- Austria
- Prior art keywords
- cox
- cyclooxygenase
- endoperoxyde
- prostaglandin
- biosynthesis inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000003180 prostaglandins Chemical class 0.000 title 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 4
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 abstract 4
- 108010037464 Cyclooxygenase 1 Proteins 0.000 abstract 2
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 abstract 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 abstract 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 abstract 2
- 108010029485 Protein Isoforms Proteins 0.000 abstract 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract 2
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/18—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91866197A | 1997-08-22 | 1997-08-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE319691T1 true ATE319691T1 (de) | 2006-03-15 |
Family
ID=25440748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98944529T ATE319691T1 (de) | 1997-08-22 | 1998-08-20 | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1005460B1 (enExample) |
| JP (1) | JP2002511887A (enExample) |
| AT (1) | ATE319691T1 (enExample) |
| CA (1) | CA2294548A1 (enExample) |
| CY (1) | CY1105027T1 (enExample) |
| DE (1) | DE69833774T2 (enExample) |
| DK (1) | DK1005460T3 (enExample) |
| ES (1) | ES2260846T3 (enExample) |
| PT (1) | PT1005460E (enExample) |
| WO (1) | WO1999010332A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| BR9813998A (pt) | 1997-11-19 | 2000-09-26 | Kowa Co | Novos derivados de piridazina e produtos medicinais contendo os mesmos como ingredientes efetivos |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| CN1279026C (zh) * | 1998-10-27 | 2006-10-11 | 艾博特公司 | 前列腺素内过氧化物h合酶生物合成抑制剂 |
| JP2000247959A (ja) | 1999-02-26 | 2000-09-12 | Kowa Co | ピリダジン−３−オン誘導体及びこれを含有する医薬 |
| EA008242B1 (ru) | 1999-12-08 | 2007-04-27 | Фармация Корпорейшн | Композиции на основе ингибитора циклооксигеназы-2 с быстро наступающим терапевтическим действием и способы лечения заболеваний |
| CA2393724A1 (en) | 1999-12-23 | 2001-06-28 | Nitromed, Inc. | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use |
| US6664256B1 (en) | 2000-07-10 | 2003-12-16 | Kowa Co., Ltd. | Phenylpyridazine compounds and medicines containing the same |
| AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
| AU2003279622A1 (en) | 2002-06-28 | 2004-01-19 | Nitromed, Inc. | Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use |
| EP1604984A1 (en) | 2003-03-18 | 2005-12-14 | Kowa Co., Ltd. | Water-soluble phenylpyridazine derivative and medicine containing the same |
| EP1745791B1 (en) | 2003-05-07 | 2013-06-26 | Osteologix A/S | Treating cartilage/bone conditions with water-soluble strontium salts |
| EP1650195A4 (en) * | 2003-07-30 | 2008-09-17 | Kowa Co | METHOD FOR INHIBITING OSTEOPONTIN PRODUCTION |
| DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| AU2006244072B2 (en) | 2005-05-10 | 2012-09-20 | Intermune, Inc. | Pyridone derivatives for modulating stress-activated protein kinase system |
| DE102005057924A1 (de) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102006037478A1 (de) * | 2006-08-10 | 2008-02-14 | Merck Patent Gmbh | 2-(Heterocyclylbenzyl)-pyridazinonderivate |
| DE102007025718A1 (de) * | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| CN110452216B (zh) | 2014-04-02 | 2022-08-26 | 英特穆恩公司 | 抗纤维化吡啶酮类 |
| US11096924B2 (en) | 2016-09-07 | 2021-08-24 | Trustees Of Tufts College | Combination therapies using immuno-dash inhibitors and PGE2 antagonists |
| WO2022195579A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3934436A1 (de) * | 1989-06-01 | 1991-04-18 | Thomae Gmbh Dr K | 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
-
1998
- 1998-08-20 CA CA002294548A patent/CA2294548A1/en not_active Abandoned
- 1998-08-20 DE DE69833774T patent/DE69833774T2/de not_active Expired - Fee Related
- 1998-08-20 PT PT98944529T patent/PT1005460E/pt unknown
- 1998-08-20 EP EP98944529A patent/EP1005460B1/en not_active Expired - Lifetime
- 1998-08-20 ES ES98944529T patent/ES2260846T3/es not_active Expired - Lifetime
- 1998-08-20 JP JP51459699A patent/JP2002511887A/ja not_active Ceased
- 1998-08-20 WO PCT/US1998/017618 patent/WO1999010332A1/en not_active Ceased
- 1998-08-20 DK DK98944529T patent/DK1005460T3/da active
- 1998-08-20 AT AT98944529T patent/ATE319691T1/de not_active IP Right Cessation
-
2006
- 2006-05-09 CY CY20061100599T patent/CY1105027T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE69833774T2 (de) | 2007-04-26 |
| WO1999010332A1 (en) | 1999-03-04 |
| JP2002511887A (ja) | 2002-04-16 |
| CA2294548A1 (en) | 1999-03-04 |
| CY1105027T1 (el) | 2010-03-03 |
| EP1005460A1 (en) | 2000-06-07 |
| DE69833774D1 (en) | 2006-05-04 |
| DK1005460T3 (da) | 2006-07-10 |
| PT1005460E (pt) | 2006-07-31 |
| EP1005460B1 (en) | 2006-03-08 |
| ES2260846T3 (es) | 2006-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE302759T1 (de) | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren | |
| CA2299300A1 (en) | Arylpyridazinones as prostaglandin endoperoxide h synthase bisoynthesis inhibitors | |
| ATE319691T1 (de) | Prostaglandin endoperoxyde h synthase biosynthese inhibitoren | |
| Reddy et al. | C-Phycocyanin, a selective cyclooxygenase-2 inhibitor, induces apoptosis in lipopolysaccharide-stimulated RAW 264.7 macrophages | |
| Carabaza et al. | Stereoselective inhibition of inducible cyclooxygenase by chiral nonsteroidal antiinflammatory drugs | |
| Frölich | A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes | |
| Esser et al. | Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2 | |
| Chan et al. | Rofecoxib [Vioxx, MK-0966; 4-(4′-methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles | |
| Storey | Evidence for a reduced transcriptional state during hibernation in ground squirrels | |
| Zschocke et al. | Cryptocarya species—substitute plants for Ocotea bullata? A pharmacological investigation in terms of cyclooxygenase-1 and-2 inhibition | |
| BRPI0011172B8 (pt) | derivados do 4,5-diaril-3(2h)-furanona como inibidores de ciclooxigenase-2 | |
| EP1391201A4 (en) | MEDICAL COMPOSITIONS | |
| Ramalho et al. | The search for new COX-2 inhibitors: a review of 2002–2008 patents | |
| Chen et al. | Syntheses and biological activities of sulfoximine-based acyclic triaryl olefins | |
| Singh Bahia et al. | Inhibitors of microsomal prostaglandin E2 synthase‐1 enzyme as emerging anti‐inflammatory candidates | |
| Aprioku et al. | Renal effects of non-steroidal anti inflammatory drugs in albino rats | |
| WO2004047772A3 (en) | Catalytic antioxidants and methods of use | |
| Biava | Introduction to COX inhibitors | |
| Klein et al. | Generation of 8‐epi‐prostaglandin F2α in isolated rat kidney glomeruli by a radical‐independent mechanism | |
| TR200000478T2 (tr) | Prostaglandin endoperoksit H sentaz biyosentezi inhibitörleri olarak arilpiridazinonlar. | |
| Zhu et al. | Cardioprotective effects of nitroparacetamol and paracetamol in acute phase of myocardial infarction in experimental rats | |
| Narayan et al. | Role of Pterocarpus santalinus against mitochondrial dysfunction and membrane lipid changes induced by ulcerogens in rat gastric mucosa | |
| Rowland et al. | Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic,[3-(3, 4-difluorophenyl)-4-(4-(methylsulfonyl) phenyl)-2-(5H)-furanone], in multiple preclinical species | |
| McCulloch et al. | Fluorescent Mechanism‐Based Probe for Aerobic Flavin‐Dependent Enzyme Activity | |
| Forghani et al. | Analysis of prostaglandin G/H synthase-2 inhibition using peroxidase-induced luminol luminescence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1005460 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |